Active — Not RecruitingPhase 4

A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients

United States200 participantsStarted 2020-09-10

Plain-language summary

This study is being done to determine the effectiveness of using a combination of two different drugs in preventing the transmission of HCV from a HCV positive donor to a HCV negative solid organ recipient.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria: * Listed kidney, heart, lung and/or pancreas patients who are negative for chronic hepatitis C infection * Willing to accept and consent for accepting hepatitis C positive graft Exclusion criteria: * Existing chronic liver disease (liver cirrhosis) * Concomitant infection with HIV or Chronic hepatitis B * Patient or any member of patient family or care giver team who does not understand or accept the risk of an acquired HCV infection * Pregnancy (Pregnant patients do not undergo solid organ transplants)

What they're measuring

Rate of prevention of HCV viremia in recipients of HCV viremic solid organs

Timeframe: 3 months

Graft and patient survival

Timeframe: 1 year

Trial details

NCT IDNCT04508907

SponsorMayo Clinic

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-11-01

View on ClinicalTrials.gov More Hepatitis C trials